
Leishmaniasis, as a tropical and subtropical disease, is endemic in more than 90 countries around the world. Today, cutaneous leishmaniasis (CL) that affects more than 1.5 million people per year lacks a definitive treatment approach. Imatinib is an anticancer drug that inhibits the abnormal function of Bcr-Abl due to its tyrosine kinase inhibitor, and that was the reason why the drug was tested for CL treatment because protein kinases are essential enzymes in the Leishmania genus. In this study, the L. major CL model of Balb/c mice was produced by injection of the cultured metacyclic form of parasite at the base of the tail. The possible recovery of CL ulcers and determination of the optimum dose of imatinib against Leishmania amastigotes were evaluated. A significant decrease was observed in mice treated with amphotericin B (positive control group) as well as imatinib 50 mg/kg compared to the unreceived drug, negative control group (P<0.05). This study could be promising in gaining insight into the potential of imatinib as an effective treatment approach against CL.
Citation: Mohsen Moslehi, Fatemeh Namdar, Mahsa Esmaeilifallah, Fariba Iraji, Bahareh Vakili, Fatemeh Sokhanvari, Seyed-Mohsen Hosseini, Faham Khamesipour, Zahra Sebghatollahi, Sayed-Hossein Hejazi. Study of therapeutic effect of different concentrations of imatinib on Balb/c model of cutaneous leishmaniasis[J]. AIMS Microbiology, 2020, 6(2): 152-161. doi: 10.3934/microbiol.2020010
[1] | Sudarshan Tiwari, Axel Klar, Giovanni Russo . Interaction of rigid body motion and rarefied gas dynamics based on the BGK model. Mathematics in Engineering, 2020, 2(2): 203-229. doi: 10.3934/mine.2020010 |
[2] | Alessia Nota, Juan J. L. Velázquez . Homoenergetic solutions of the Boltzmann equation: the case of simple-shear deformations. Mathematics in Engineering, 2023, 5(1): 1-25. doi: 10.3934/mine.2023019 |
[3] | Luis Silvestre, Stanley Snelson . Solutions to the non-cutoff Boltzmann equation uniformly near a Maxwellian. Mathematics in Engineering, 2023, 5(2): 1-36. doi: 10.3934/mine.2023034 |
[4] | Youchan Kim, Seungjin Ryu, Pilsoo Shin . Approximation of elliptic and parabolic equations with Dirichlet boundary conditions. Mathematics in Engineering, 2023, 5(4): 1-43. doi: 10.3934/mine.2023079 |
[5] | Jonathan A. D. Wattis . Asymptotic approximations to travelling waves in the diatomic Fermi-Pasta-Ulam lattice. Mathematics in Engineering, 2019, 1(2): 327-342. doi: 10.3934/mine.2019.2.327 |
[6] | Alessandra De Luca, Veronica Felli . Unique continuation from the edge of a crack. Mathematics in Engineering, 2021, 3(3): 1-40. doi: 10.3934/mine.2021023 |
[7] | Nickolas Giardetti, Amy Shapiro, Stephen Windle, J. Douglas Wright . Metastability of solitary waves in diatomic FPUT lattices. Mathematics in Engineering, 2019, 1(3): 419-433. doi: 10.3934/mine.2019.3.419 |
[8] | Andrea Kubin, Lorenzo Lamberti . Variational analysis in one and two dimensions of a frustrated spin system: chirality and magnetic anisotropy transitions. Mathematics in Engineering, 2023, 5(6): 1-37. doi: 10.3934/mine.2023094 |
[9] | Hoai-Minh Nguyen, Tu Nguyen . Approximate cloaking for the heat equation via transformation optics. Mathematics in Engineering, 2019, 1(4): 775-788. doi: 10.3934/mine.2019.4.775 |
[10] | Antonio DiCarlo, Paolo Podio-Guidugli . From point particles to body points. Mathematics in Engineering, 2022, 4(1): 1-29. doi: 10.3934/mine.2022007 |
Leishmaniasis, as a tropical and subtropical disease, is endemic in more than 90 countries around the world. Today, cutaneous leishmaniasis (CL) that affects more than 1.5 million people per year lacks a definitive treatment approach. Imatinib is an anticancer drug that inhibits the abnormal function of Bcr-Abl due to its tyrosine kinase inhibitor, and that was the reason why the drug was tested for CL treatment because protein kinases are essential enzymes in the Leishmania genus. In this study, the L. major CL model of Balb/c mice was produced by injection of the cultured metacyclic form of parasite at the base of the tail. The possible recovery of CL ulcers and determination of the optimum dose of imatinib against Leishmania amastigotes were evaluated. A significant decrease was observed in mice treated with amphotericin B (positive control group) as well as imatinib 50 mg/kg compared to the unreceived drug, negative control group (P<0.05). This study could be promising in gaining insight into the potential of imatinib as an effective treatment approach against CL.
HF: Heart failure; ceRNA: competing endogenous RNA; lncRNAs: long noncoding RNAs; miRNAs: microRNAs; CAD: coronary artery disease; ncRNAs: Noncoding RNAs; DAVID: Database for Annotation, Visualization, and Integrated Discovery; PPI: Protein-protein Interaction; STRING: Search Tool for the Retrieval of Interacting Genes; DELs: differentially expressed lncRNAs; DEMs: differentially expressed mRNAs; DEMis: differentially expressed miRNAs; BP: biological process; CC: cell component; MF: molecular function; WEE1: WEE1 G2 checkpoint kinase; MCM7: mini-chromosome maintenance complex component 7; E2F2: E2F transcription factor 2
Heart failure, a syndrome characterized by cardiac dysfunction-caused signs as well as symptoms, are recognized as an important cause of global morbidity and mortality [1]. An estimated 64.3 million people are living with heart failure worldwide, HF prevalence is generally estimated at 1-2% in Western countries while HF incidence reaches 5-10 per 1000 persons annually [2,3]. HF could be caused by multiple situations, such as high blood pressure, coronary artery disease (CAD), valvular and congenital heart disease as well as cardiomyopathies [4,5,6]. Various existing researches have shed new lights on the pathobiology and molecular mechanism of HF. Nevertheless, it is still unclarified of the exact molecular etiology, which deserves further exploration to reveal new therapeutic targets.
Noncoding RNAs (ncRNAs) have been reported to be critically involved in various diseases [7]. Long noncoding RNAs are the largest class of ncRNAs and are defined as transcribed RNA molecules > 200 nucleotides in length and without significant protein-coding potential [8]. Accumulative researches have recently revealed the functions of lncRNAs in multiple biological activities [9], with aberrant expression of lncRNAs in HF [10,11].
Growing attention has been paid to the vital roles of miRNAs in cardiovascular disorders, including HF [12]. Additionally, lncRNA is capable of modulating mRNA expression via the interaction with miRNA, giving rise to ceRNA hypothesis [13]. Nevertheless, the correlation between HF ceRNA remains barely clarified.
This research might offer a new regulatory mechanism between noncoding and coding RNAs in HF, and also widen the understanding concerning the development and progression of HF.
GEO publicly provides genomic data to support MIAME-compliant data submissions [14]. Human lncRNA, miRNA and mRNA expression were freely accessible from NCBI-GEO (GSE124401 and GSE136547). To be specific, the threshold of up-regulated or down-regulated lncRNA/mRNA was |log2 (fold-change) | > 1 with adjust P < 0.05; the significant difference in miRNA data was |log2 (fold-change) | > 0.5 with adjust P < 0.05.
The ceRNA network establishment was based on miRcode (http://www.mircode.org/) [15], miRDB (http://mirdb.org/) [16], miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/php/index.php) [17] as well as TargetScan (http://www.targetscan.org/mamm_31/) [18] databases.
The detailed process was listed as follows: (1) the prediction of lncRNAs-targeted differential miRNAs by the highly conserved miRNA family of miRcode databases; (2) the prediction of mRNAs targeted by candidate miRNAs via TargetScan, miRTarBase as well as miRDB databases, wherein all predictive values should satisfy a matching number of 3; (3) the final construction of ceRNA network was accomplished by combining differential lncRNAs, miRNAs and miRNA-targeted mRNAs; (4)Cytoscape version 3.5.1(https://cytoscape.org/) was adopted for constructing and visualizing the lncRNA-miRNA-mRNA network, followed by calculation of all node degrees of the ceRNA network.
Database for Annotation, Visualization, and Integrated Discovery (DAVID 6.8, https://david.ncifcrf.gov/) was utilized for analyzing functional enrichment. Moreover, we also explored the biological processes in Gene Ontology (GO) as well as Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) (p < 0.05).
For assessing the associations among DEGs within the ceRNA network, this study adopted the Search Tool for the Retrieval of Interacting Genes (STRING, https://string-db.org/) to comprehensively examine protein-gene interactions and construct a PPI network based on the ceRNA network. Afterwards, our constructed PPI network was visualized using Required Confidence (combined score) > 0.4 [19]. Thereafter, gene topology within this PPI network was analyzed by Cytoscape, and scale-free PPI network was utilized to detect pivotal proteins.
Cytoscape software was employed to extract all lncRNAs along with their relevant mRNAs as well as miRNAs in the global triple network for novel subnetwork construction, followed by calculation of the number of relevant lncRNA-miRNA-mRNA triplets. We further revealed target lncRNAs via the comparison of lncRNA node degree as well as relevant lncRNA-miRNA and miRNA-mRNA.
GSE124401 and GSE136547 was used for extracting human lncRNA/mRNA expression profile. The -pre-processing of raw data revealed 2587 differentially expressed genes (DEGs) (Figure 1A), including 694 differentially expressed lncRNAs (DELs), among which 472 DELs were up-regulated and 222 DELs were down-regulated (Figure 1B). Moreover, there were 2115 differentially expressed mRNAs (DEMs), including 1254 up-regulated DEMs and 861 down-regulated DEMs (Figure 1C). Besides, there were 67 differentially expressed miRNAs (DEMis), including 32 up-regulated DEMis and 35down-regulated ones (Figure 2A, 2B).
The ceRNA network analysis was further performed. In total, TargetScan, miRDB as well as miRTarBase databases successfully predicted 96 pairs of miRNA-mRNA interactions, and miRcode database successfully predicted 156 pairs of IncRNA-miRNA interactions. Cytoscape was further adopted for visualizing ceRNA network establishment. Finally, we successfully established the lncRNA-miRNA-mRNA network consisting of 82 lncRNA nodes, 58 mRNA nodes as well as 5 miRNA nodes (Figure 3). The gene expression is shown in Tables 1-3.
DELs | Gene names |
Upregulated | SLC9A9-AS2, LINC00482, U52111, AC018730, AC131157, AC105935, AP000320, AL136115, RUSC1-AS1, NCBP2-AS1, AC093642, AP001505, AC093734, SRGAP3-AS2, ATXN8OS, C4B-AS1, AC090044, TTC3-AS1, AC009237, AC016716, HCG27, FAM138E, AC103681, AC010907, AC092580, XIST, AC084149, LINC00051, AC009264, AC108142, AP002414, LINC00343, AC074286, AP001056, PRICKLE2-AS3, LGALS8-AS1, AP002478, KCNQ1OT1, AL137003, AC073133, AP000146, AP003774, TTTY14, AC087491, AC092614, AP003025, HCG22, AC005042, AC093110, CTC-338M12, AC079354, AC090286, FAM66E, AC010731, AC087392, HPYR1, VCAN-AS1, FAM66C, AC006019 |
Downregulated | AC090193, ZNRF3-AS1, LINC00200, AC007255, MIR600HG, SRGAP3-AS4, AL928742, C8orf31, FAM99B, AC006003, AC009313, AP002381, AP000472, AC010336, AC073934, AC025442, AC008079, AC090587, AC063977, POU6F2-AS2, AC011374, AL160271, AC073094 |
DEMs | Gene names |
Upregulated | RUNX1T1, KIAA1147, SNCG, PPP1R15B, PLEKHM1, DNAJC27, TRIM35, USP32, RGMB, FBXO21, CERCAM, OTUD7B, SMAD5, SOX4, NPAT, CCL1, RAP2C, UBE2Q2, NPAS2, RIMS3, KLHL28, E2F2, REST, KLK10, MCM7, KLF3, ESRRA, TARBP2, NPAS3, PKNOX1, TET3, GIGYF1, CYBRD1, NR2C2, RORA, CNNM2, ARHGAP35, IGSF3, KIF23, WEE1 |
Downregulated | CAPN15, NIPA1, KMT2B, GLRX5, WAC, SIRT7, SGTB, MASTL, ANKRD13C, RPA2, LAMC1, AGO1, CPEB3, BAZ2A, SMARCE1, ANKRD52, RLIM, GID4 |
DEMis | Gene names |
Upregulated | hsa-miR-140-5p, hsa-miR-107, hsa-miR-17-5p, hsa-miR-20b-5p |
Downregulated | hsa-miR-125a-5p |
We analyze 58 mRNA in the ceRNA network. GO analysis revealed the significant enrichment of DEGs in transcription regulation (including positive and negative regulation of transcription), positive regulation of apoptotic process as well as miRNAs generation involved in gene silencing by miRNA in terms of biological process (BP) changes (Figure 4A); nucleoplasm, nucleus and cytoplasm in terms of cell component (CC) changes (Figure 4B); DNA binding, protein binding as well as transcription factor activity in terms of molecular function (MF) changes (Figure 4C). KEGG pathway analysis identified the enrichment of DEGs in cell cycle, circadian rhythm and DNA replication (Table 4).
Term | Count | % | P value | Genes |
hsa04110: Cell cycle | 3 | 5.17241 | 0.0367 | WEE1, MCM7, E2F2 |
hsa04710: Circadian rhythm | 2 | 3.44828 | 0.07399 | RORA, NPAS2 |
hsa03030: DNA replication | 2 | 3.44828 | 0.08543 | MCM7, RPA2 |
Next mRNAs from ceRNA network were up-loaded to STRING database for further identification of key mRNAs in the HF-associated ceRNA network. we established a PPI network, we hide disconnected nodes in the network. The PPI network revealed 30 nodes and 27 edges (Figure 5A). Afterwards., degree of linkage between DEMs was adopted to select key mRNAs from PPI network, which gave rise to key mRNAs, including WEE1 G2 checkpoint kinase (WEE1), minichromosome maintenance complex component 7 (MCM7), E2F transcription factor 2 (E2F2) (Figure 5B). The scores of these genes were far higher than others. Notably, E2F2, WEE1 and MCM7, which were extensively studied, were also involved in the subnetwork, which was indicative of the regulatory role of s the subnetwork on biological activities via diverse pathways.
For further identification of hub RNAs as well as their relevant networks, Cytoscape plugin cytoHubba was utilized for calculation of all node degrees in the ceRNA network. To be specific, AC010336, KCNQ1OT1 and XIST were three of the top-ranked nodes, which all had 5 target miRNA, indicating their significance in regulating transcription, all consisting of 1 lncRNA node, 5 miRNA nodes as well as 58 mRNA nodes (Figure 6A), Five miRNAs serve as the center of ceRNA, a subnetwork of lncRNA-miR-17-5p-mRNA, lncRNA-miR-20b-5p-mRNA, lncRNA-miR-107-mRNA, lncRNA-miR-125a-5p-mRNA and lncRNA-miR-140-5p-mRNA was extracted from the ceRNA network (Figure 6B-F), The information on the ceRNA network for lncRNA-miRNA-mRNA ceRNA are shown in Table 5.
HF is caused by myocardial defects from either functional or structural aspects, further leading to impaired ventricular filling or blood ejection, which is a common clinical syndrome. Moreover, HF is recognized as a universal disorder with a high rate of morbidity, hospitalization as well as mortality worldwide [20,21].
Recently, more attention has been paid to ncRNAs owing to the rapidly developed high-throughput genomic platforms, which have been uncovered to be critically involved in modulating diverse biological activities, including metabolism, differentiation as well as development. Despite rapid progress, its representative molecular signatures are still incompletely clear, especially their roles in HF progression. LncRNAs are capable of binding to complementary binding sites of miRNAs and modulating gene expression by sponging 3'-UTR of downstream target genes [13]. By guiding transcript stability, nuclear export, subcellular localization and translation efficiency, RNA 3′-end cleavage and polyadenylation play an important role in pathogenesis, diagnosis and therapy of human disorders [22,23]. A substantial amount of genes with a potential role in HF seem to be in fact regulated at the RNA 3'end, as summarized in the article written by Jamie Nourse and Stefano Spada [23]. The regulation of RNA 3'end also influences binding of miRNAs and lnRNAs. Therefore, a comprehensive understanding of the RNA regulatory network sheds novel light on gene regulatory mechanisms.
Therefore, interaction data from GEO were extracted for creating a global triple network on the basis of the ceRNA theory, indicating the same miRNA shared by lncRNAs and mRNAs in one triplet. To be specific, 82 lncRNA nodes, 5 miRNA nodes, 58 mRNA nodes as well as 244 edges were contained in the lncRNA-miRNA-mRNA network. GO and KEGG analysis was conducted for better annotation of the biological functions of downstream mRNAs. Remarkably enriched KEGG pathways were cell cycle pathways, which have been reported to be involved in mechanism of regulating HF, causing apoptosis and proliferation of HF [24,25,26]. Through the analysis of GO, we observed that a large number of genes were located in nucleoplasm, nucleus and cytoplasm, suggesting that these genes participate in regulation of transcription by DNA binding.
We further calculated the hub nodes for identification of possible key gene candidates as diagnostic biomarkers as well as therapeutic targets of HF. Of note, hub nodes that share high degree of connectivity to other ones might be utilized as topological markers of the ceRNA network for further assessment of important genes. Three lncRNAs (AC010336, KCNQ1OT1 and XIST) had significantly higher degrees than other lncRNA nodes and were therefore identified as key hub nodes. Due to the similar miRNA targets, the above three lncRNAs showed common trends in terms of significant GO terms.
LncRNA Kcnq1ot1, localized in KCNQ1 locus at 11p15.5 [27], has been previously demonstrated have correlation with multiple diseases, especially heart disease [28,29,30]. In a new study, significant up-regulation of Kcnq1ot1 was found in DCM. Bioinformatics as well as luciferase assays shown that Kcnq1ot1 could function as a ceRNA for modulating caspase-1 expression by sponging miR-214-3p in high glucose-treated cardiac fibroblasts [31]. Moreover, KCNQ1OT1 not only is capable of mediating pyroptosis in diabetic cardiomyopathy, but also aggravates cardiomyocyte apoptosis by targeting FUS in HF [32]. In acute myocardial infarction model, lncRNA Kcnq1ot1 renders cardiomyocytes apoptosis by up-regulating Tead1 [33].
lncRNA XIST also plays essential roles in different types of diseases [34,35,36], which can modulate cardiac hypertrophy through targeting miR-101 [37]. LncRNA XIST knockdown could repress myocardial cell apoptosis in AMI model rats by downregulating miR-449 level [38]. In addition, XIST suppression was capable of relieving myocardial I/R injury by regulating miR-133a/SOCS2 axis as well as suppressing autophagy in a study investigating the functions of lncRNA XIST in myocardial I/R injury both in vitro and in vivo [39].
Previous studies have shown that Kcnq1ot1 and XIST regulate cardiomyocyte apoptosis in cardiac research. This is consistent to our KEGG analysis, which shows that the main pathway of ceRNA network is in cell cycle regulation. HF is dominated by cardiac remodeling, causing progressive enlargement of heart chambers and deterioration of contractile function [40]. Myocardial cell apoptosis is recognized as an important process in HF progression [41]. Apoptosis is a delicately regulated biological activity modulating the balance between pro-death and pro-survival signals, which is essential for cell fate. The majority of apoptosis signaling pathways in extra-cardiac cell types also play critical roles in inducing heart apoptosis. Human failing hearts in NYHA classes III-IV generally show apoptotic rates ranging from 0.12% to 0.70% [42,43,44,45]. Moreover, although apoptosis might not be the initial focus in several studies, apoptosis generally accompanies heart disease progression [46].
By contrast, relieving HF progression is generally accompanied with suppressed apoptosis [47]. Unlike necrosis, apoptosis is a highly and orderly modulated event. Thus, restricting cardiac muscle loss via apoptotic suppression is of therapeutic implication in HF. From KEGG and GO enrichment, KCNQ1OT1 and XIST may become therapeutic alternatives associated with apoptosis in HF.
These ncRNAs, found in tissue, participate in several pathophysiological processes associated with HF, including hypertrophy and cardiac fibrosis. Micro RNAs are single-stranded ncRNAs with 22 to 24nt in length with endogenous expression [48]. Bioinformatic analysis identifies target‐specific miRNAs and regulatory hubs miRNAs to many novel pathophysiological processes, such as hemostatic system [49]. Besides, miRNAs have been shown to be of diagnostic and prognostic value in HF [50,51,52].
Hsa-miR-17-5p, hsa-miR-20b-5p, hsa-miR-107, hsa-miR-125a-5p as well as hsa-miR-140-5p are center of ceRNA. Besides, miRNA can modulate various cellular process. For example, knockdown of miR-17-5p suppresses proliferation and autophagy, but enhances apoptosis in thyroid tumor by targeting PTEN. MiR-20b-5p is capable of relieving hypoxia-induced apoptosis in cardiomyocytes through HIF-1α/NF-κB pathway [53]. miR-107 is capable of regulating apoptosis, synthesis of extracellular matrix as well as proliferation of chondrocytes by targeting PTEN [54]. Recently, a new class of RNA therapeutic has attracted considerable attention, that of miRNA targeting. RNA-based therapeutics have attracted considerable attention in the past decade because of their potential to treat numerous diseases, including cardiovascular disorders [55]. There are many researches showing the discovery of miRNA-based therapeutic targets in the hemostatic system [56] In the future, RNA-based therapies also have strong appeal in the treatment of cardiovascular diseases.
Collectively, this study uncovered the expression profiles of DEMs, DELs and DEMis, followed by prediction of their functions as well as potential pathways in HF. Nevertheless, intervention assays of RNAs were not performed in this research, which is a limitation and requires further validations of possible roles of these RNAs on HF.
The datasets generated and/or analysed during the current study are available in the GEO database, https://www.ncbi.nlm.nih.gov/geo/
Qin Zhang: Conceptualization, Methodology, Writing Reviewing, Xudan Ma: Editing, Software, Weina Pang: Data curation, Writing- Original draft preparation. Qijun Zhang: Visualization, Investigation. Kefeng Huang and Haihong Zhu: Supervision.
This study was supported by the Natural Science Foundation of Zhejiang Province (Effect of lncRNA MHRT on dedifferentiation like state of cardiomyocytes in patients with atrial fibrillation and its mechanism) (LY20H020001).
The authors declare that they have no competing interests.
[1] |
Ghorbani M, Farhoudi R (2018) Leishmaniasis in humans: drug or vaccine therapy? Drug Des Devel Ther 12: 25-40. doi: 10.2147/DDDT.S146521
![]() |
[2] | Lindoso JA, Cunha MA, Queiroz IT, et al. (2016) Leishmaniasis–HIV coinfection: current challenges. HIV/AIDS 8: 147. |
[3] |
Bahrami F, Harandi AM, Rafati S (2018) Biomarkers of cutaneous leishmaniasis. Front Cell Infect Microbiol 8: 222. doi: 10.3389/fcimb.2018.00222
![]() |
[4] |
Mendonça SC (2016) Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discovery. Parasites Vectors 9: 492. doi: 10.1186/s13071-016-1777-x
![]() |
[5] |
Apostolopoulos N, Mitropoulou A, Thom N, et al. (2018) Update on therapy and prevention of canine leishmaniasis. Tierarztl Prax Ausg K Kleintiere Heimtiere 46: 315-322. doi: 10.15654/TPK-180089
![]() |
[6] | Kaiming B, Yuyang C, Songnian Z, et al. (2018) Current visceral leishmaniasis research: a research review to inspire future study. BioMed Res Intl 2018: 1-13. |
[7] |
Norouzinezhad F, Ghaffari F, Norouzinejad A, et al. (2016) Cutaneous leishmaniasis in Iran: Results from an epidemiological study in urban and rural provinces. Asian Pac J Trop Biomed 6: 614-619. doi: 10.1016/j.apjtb.2016.05.005
![]() |
[8] |
Adriaensen W, Dorlo TPC, Guido V, et al. (2018) Immunomodulatory therapy of visceral leishmaniasis in human immunodeficiency virus-coinfected patients. Front Immunol 8: 1943. doi: 10.3389/fimmu.2017.01943
![]() |
[9] |
de Vries HJ, Reedijk SH, Schallig HD (2015) Cutaneous leishmaniasis: recent developments in diagnosis and management. Am J Clin Dermatol 16: 99-109. doi: 10.1007/s40257-015-0114-z
![]() |
[10] |
Alcântara LM, Ferreira TCS, Gadelha FR, et al. (2018) Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis. Int J Parasitol Drugs Drug Resist 8: 430-439. doi: 10.1016/j.ijpddr.2018.09.006
![]() |
[11] |
Hotez PJ, Bottazzi ME, Strych U (2016) New vaccines for the world's poorest people. Annu Rev Med 67: 405-417. doi: 10.1146/annurev-med-051214-024241
![]() |
[12] |
Moen MD, McKeage K, Plosker GL, et al. (2007) Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 67: 299-320. doi: 10.2165/00003495-200767020-00010
![]() |
[13] |
O'Connell EM, Bennuru S, Steel C, et al. (2015) Targeting Filarial Abl-like Kinases: Orally Available, Food and Drug Administration–Approved Tyrosine Kinase Inhibitors Are Microfilaricidal and Macrofilaricidal. Int J Infect Dis 212: 684-693. doi: 10.1093/infdis/jiv065
![]() |
[14] |
Kesely KR, Pantaleo A, Turrini FM, et al. (2016) Inhibition of an erythrocyte tyrosine kinase with imatinib prevents Plasmodium falciparum egress and terminates parasitemia. PloS one 11. doi: 10.1371/journal.pone.0164895
![]() |
[15] |
Alvarez-Rueda N, Biron M, Le Pape (2009) Infectivity of Leishmania mexicana is associated with differential expression of protein kinase C-like triggered during a cell-cell contact. PLoS One 4. doi: 10.1371/journal.pone.0007581
![]() |
[16] |
Hodgson J (2001) ADMET—turning chemicals into drugs. Nat Biotechnol 19: 722-726. doi: 10.1038/90761
![]() |
[17] |
Potts RO, Guy RH (1992) Predicting skin permeability. Pharm Res 9: 663-669. doi: 10.1023/A:1015810312465
![]() |
[18] | Moslehi M, Namdar F, Esmaeilifallah M, et al. (2019) Evaluation of different concentrations of imatinib on the viability of Leishmania major: An In Vitro study. Adv Biomed Res 8. |
[19] |
Ponte-Sucre A, Gamarro F, Dujardin JC, et al. (2017) Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis 11. doi: 10.1371/journal.pntd.0006052
![]() |
[20] |
Vakili B, Eslami M, Hatam GR, et al. (2018) Immunoinformatics-aided design of a potential multi-epitope peptide vaccine against Leishmania infantum. Int J Biol Macromol 120: 1127-1139. doi: 10.1016/j.ijbiomac.2018.08.125
![]() |
[21] |
Scott P, Novais FO (2016) Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat Rev Immunol 16: 581-592. doi: 10.1038/nri.2016.72
![]() |
[22] |
Vakili B, Nezafat N, Zare B, et al. (2020) A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice. Med Microbiol Immunol 209: 69-79. doi: 10.1007/s00430-019-00640-7
![]() |
[23] |
Bekhit AA, El-Agroudy E, Helmy A, et al. (2018) Leishmania treatment and prevention: Natural and synthesized drugs. Eur J Med Chem 160: 229-244. doi: 10.1016/j.ejmech.2018.10.022
![]() |
[24] |
Vakili B, Nezafat N, Hatam GR, et al. (2018) Proteome-scale identification of Leishmania infantum for novel vaccine candidates: A hierarchical subtractive approach. Comput Biol Chem 72: 16-25. doi: 10.1016/j.compbiolchem.2017.12.008
![]() |
[25] |
Kennedy JA, Hobbs G (2018) Tyrosine kinase inhibitors in the treatment of chronic-phase CML: Strategies for frontline decision-making. Curr Hematol Malig Rep 13: 202-211. doi: 10.1007/s11899-018-0449-7
![]() |
[26] |
Katz N, Couto FFB, Araújo N (2013) Imatinib activity on Schistosoma mansoni. Mem Inst Oswaldo Cruz 108: 850-853. doi: 10.1590/0074-0276130207
![]() |
[27] |
Beckmann S, Long T, Scheld C, et al. (2014) Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor Imatinib. Int J Parasitol Drugs Drug Resist 4: 287-295. doi: 10.1016/j.ijpddr.2014.07.005
![]() |
[28] |
Naula C, Parsons M, Mottram JC (2005) Protein kinases as drug targets in trypanosomes and Leishmania. Biochim Biophys Acta 1754: 151-159. doi: 10.1016/j.bbapap.2005.08.018
![]() |
[29] |
Handman E, Bullen DV (2002) Interaction of Leishmania with the host macrophage. Trends Parasitol 18: 332-334. doi: 10.1016/S1471-4922(02)02352-8
![]() |
[30] |
Sanderson L, Yardley V, Croft SL (2014) Activity of anticancer protein kinase inhibitors against Leishmania spp. J Antimicrob Chemother 69: 1888-1891. doi: 10.1093/jac/dku069
![]() |
[31] |
Matsushita M, Kawaguchi M (2018) Immunomodulatory effects of drugs for effective cancer immunotherapy. J Oncol 2018. doi: 10.1155/2018/8653489
![]() |
[32] |
Hahn T, Polanczyk MJ, Borodovsky A, et al. (2013) Use of anticancer drugs, mitocans, to enhance the immune responses against tumors. Curr Pharm Biotechnol 14: 357-376. doi: 10.2174/1389201011314030010
![]() |
[33] |
Al-Abdely HM, Graybill JR, Bocanegra R, et al. (1998) Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis. Antimicrob Agents Chemother 42: 2542-2548. doi: 10.1128/AAC.42.10.2542
![]() |
[34] | Dahiya M, Dureja H (2016) Central composite designed imatinib-loaded magnetic nanoparticles. Recent Pat Nanotechnol 6: 146-155. |
DELs | Gene names |
Upregulated | SLC9A9-AS2, LINC00482, U52111, AC018730, AC131157, AC105935, AP000320, AL136115, RUSC1-AS1, NCBP2-AS1, AC093642, AP001505, AC093734, SRGAP3-AS2, ATXN8OS, C4B-AS1, AC090044, TTC3-AS1, AC009237, AC016716, HCG27, FAM138E, AC103681, AC010907, AC092580, XIST, AC084149, LINC00051, AC009264, AC108142, AP002414, LINC00343, AC074286, AP001056, PRICKLE2-AS3, LGALS8-AS1, AP002478, KCNQ1OT1, AL137003, AC073133, AP000146, AP003774, TTTY14, AC087491, AC092614, AP003025, HCG22, AC005042, AC093110, CTC-338M12, AC079354, AC090286, FAM66E, AC010731, AC087392, HPYR1, VCAN-AS1, FAM66C, AC006019 |
Downregulated | AC090193, ZNRF3-AS1, LINC00200, AC007255, MIR600HG, SRGAP3-AS4, AL928742, C8orf31, FAM99B, AC006003, AC009313, AP002381, AP000472, AC010336, AC073934, AC025442, AC008079, AC090587, AC063977, POU6F2-AS2, AC011374, AL160271, AC073094 |
DEMs | Gene names |
Upregulated | RUNX1T1, KIAA1147, SNCG, PPP1R15B, PLEKHM1, DNAJC27, TRIM35, USP32, RGMB, FBXO21, CERCAM, OTUD7B, SMAD5, SOX4, NPAT, CCL1, RAP2C, UBE2Q2, NPAS2, RIMS3, KLHL28, E2F2, REST, KLK10, MCM7, KLF3, ESRRA, TARBP2, NPAS3, PKNOX1, TET3, GIGYF1, CYBRD1, NR2C2, RORA, CNNM2, ARHGAP35, IGSF3, KIF23, WEE1 |
Downregulated | CAPN15, NIPA1, KMT2B, GLRX5, WAC, SIRT7, SGTB, MASTL, ANKRD13C, RPA2, LAMC1, AGO1, CPEB3, BAZ2A, SMARCE1, ANKRD52, RLIM, GID4 |
DEMis | Gene names |
Upregulated | hsa-miR-140-5p, hsa-miR-107, hsa-miR-17-5p, hsa-miR-20b-5p |
Downregulated | hsa-miR-125a-5p |
Term | Count | % | P value | Genes |
hsa04110: Cell cycle | 3 | 5.17241 | 0.0367 | WEE1, MCM7, E2F2 |
hsa04710: Circadian rhythm | 2 | 3.44828 | 0.07399 | RORA, NPAS2 |
hsa03030: DNA replication | 2 | 3.44828 | 0.08543 | MCM7, RPA2 |
DELs | Gene names |
Upregulated | SLC9A9-AS2, LINC00482, U52111, AC018730, AC131157, AC105935, AP000320, AL136115, RUSC1-AS1, NCBP2-AS1, AC093642, AP001505, AC093734, SRGAP3-AS2, ATXN8OS, C4B-AS1, AC090044, TTC3-AS1, AC009237, AC016716, HCG27, FAM138E, AC103681, AC010907, AC092580, XIST, AC084149, LINC00051, AC009264, AC108142, AP002414, LINC00343, AC074286, AP001056, PRICKLE2-AS3, LGALS8-AS1, AP002478, KCNQ1OT1, AL137003, AC073133, AP000146, AP003774, TTTY14, AC087491, AC092614, AP003025, HCG22, AC005042, AC093110, CTC-338M12, AC079354, AC090286, FAM66E, AC010731, AC087392, HPYR1, VCAN-AS1, FAM66C, AC006019 |
Downregulated | AC090193, ZNRF3-AS1, LINC00200, AC007255, MIR600HG, SRGAP3-AS4, AL928742, C8orf31, FAM99B, AC006003, AC009313, AP002381, AP000472, AC010336, AC073934, AC025442, AC008079, AC090587, AC063977, POU6F2-AS2, AC011374, AL160271, AC073094 |
DEMs | Gene names |
Upregulated | RUNX1T1, KIAA1147, SNCG, PPP1R15B, PLEKHM1, DNAJC27, TRIM35, USP32, RGMB, FBXO21, CERCAM, OTUD7B, SMAD5, SOX4, NPAT, CCL1, RAP2C, UBE2Q2, NPAS2, RIMS3, KLHL28, E2F2, REST, KLK10, MCM7, KLF3, ESRRA, TARBP2, NPAS3, PKNOX1, TET3, GIGYF1, CYBRD1, NR2C2, RORA, CNNM2, ARHGAP35, IGSF3, KIF23, WEE1 |
Downregulated | CAPN15, NIPA1, KMT2B, GLRX5, WAC, SIRT7, SGTB, MASTL, ANKRD13C, RPA2, LAMC1, AGO1, CPEB3, BAZ2A, SMARCE1, ANKRD52, RLIM, GID4 |
DEMis | Gene names |
Upregulated | hsa-miR-140-5p, hsa-miR-107, hsa-miR-17-5p, hsa-miR-20b-5p |
Downregulated | hsa-miR-125a-5p |
Term | Count | % | P value | Genes |
hsa04110: Cell cycle | 3 | 5.17241 | 0.0367 | WEE1, MCM7, E2F2 |
hsa04710: Circadian rhythm | 2 | 3.44828 | 0.07399 | RORA, NPAS2 |
hsa03030: DNA replication | 2 | 3.44828 | 0.08543 | MCM7, RPA2 |